COMPARISON BETWEEN WAIST AND HIP RATIO LEVELS IN HEALTHY WOMEN AND PATIENTS WITH POLYCYSTIC OVARY SYNDROME

Authors

  • Vesko Stoilov
  • Ivan Kostov
  • Petar Petrov Professor, D.Sc., University of agribusiness and rural development, BULGARIA Medical Institute of the Ministry of Interior, Sofia, BULGARIA
  • Ivo Dimitrov

Keywords:

index, waist, hips

Abstract

In analyzing the results we found that the largest number of patients in the control group had waist and hip ratio (WHR) values in the range of 0.75-0.8 or 40.09% of all. Second in the same group are women with a WHR of 0.8-0.85 (29.70%) who can be identified as high-risk according to the current World Health Organization (WHO) criteria. Third are women with WHR above 0.9 (10.89%).

Analyzing the results in women with Polycystic ovary syndrome (PCOS), we found that the highest number of them had values of the studied indicator between 0.85-0.9 or a total of 40.39% of all, who can be defined as high risk according to WHO. The second largest group is that of women with WHR above 0.8-0.85 (30.04%). Third is the group of women with WHR values above 0.9 (18.22%) who are considered to be at the highest risk of developing cardiovascular and metabolic complications.

References

Robeva R., Nyakoi nevroendokrinni aspekti na gonadnite narusheniya pri sastoyaniya na insulinova rezistentnost, Disertatsionen trud, Sofiya 2008.

Ardaems Y et al. PCOD: contribution of vaginal endosonography and reassessment of ultrasonic diagnosis, 1991;55, 1062-1068.

Cate RL, Mattaliano RJ, Hession C, Tizard R, Farber NM, Cheung A, Ninfa EG, Frey AZ, Gash DJ, Chow EP (June 1986). Isolation of the bovine and human genes for Müllerian inhibiting substance and expression of the human gene in animal cells. Cell 45 (5): 685– 98.

Behringer RR (1994). 5 The in Vivo Roles of Müllerian-inhibiting Substance. The in vivo roles of müllerian-inhibiting substance. Curr. Top. Dev. Biol. Current Topics in Developmental Biology 29: 171–87

Hampl, R.; Šnajderová, M.; Mardešić, T. (2011). Antimüllerian hormone (AMH) not only a marker for prediction of ovarian reserve. Physiological research / Academia Scientiarum Bohemoslovaca 60 (2): 217–223.

Imbeaud S, Faure E, Lamarre I, Mattéi MG, di Clemente N, Tizard R, Carré-Eusèbe D, Belville C, Tragethon L, Tonkin C, Nelson J, McAuliffe M, Bidart JM, Lababidi A, Josso N, Cate RL, Picard JY (December 1995). Insensitivity to anti-müllerian hormone due to a mutation in the human anti-müllerian hormone receptor. Nat. Genet. 11 (4): 382–8.

Walter F., PhD. Boron (2003). Medical Physiology: A Cellular And Molecular Approaoch. Elsevier/Saunders. p. 1300. ISBN 1-4160-2328-3.

An Introduction to Behavioral Endocrinology, Randy J Nelson, 3rd edition, Sinauer

Kelsey TW, Wright P, Nelson SM,Anderson RA, Wallace WHB (2011). A validated model of serum anti-Müllerian hormone from conception to menopause. In Vitzthum, Virginia J. PLoS ONE 6 (7): e22024. doi:10.1371/journal.pone.0022024. PMC 3137624. PMID 21789216.

Downloads

Issue

Vol. 8 No. 4 (2019): New knowledge Journal of science

Section

Health management

License

Creative Commons License

New knowledge Journal of science by Univesity of agribusiness and rural development is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Based on a work at http://science.uard.bg/index.php/newknowledge/issue/archive.
Permissions beyond the scope of this license may be available at http://science.uard.bg/index.php/newknowledge/index.